Search

Displaying results 6011 - 6020 of 10000 in total
  1. Drug

    Talabostat

    go.drugbank.com/drugs/DB06182
    Investigational

  2. Drug

    Prenylamine

    go.drugbank.com/drugs/DB04825
    ApprovedWithdrawn

    Prenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.

  3. Drug

    Felbinac

    go.drugbank.com/drugs/DB07477
    Investigational

    Categories: Antiinflammatory Preparations, Non-Steroids for Topical Use
  4. Drug

    Pafuramidine

    go.drugbank.com/drugs/DB06532
    Investigational

    Pafuramidine, a prodrug of furamidine, currently has orphan status for Pneumocystis jiroveci pneumonia.

  5. Drug

    Zileuton

    go.drugbank.com/drugs/DB00744
    ApprovedWithdrawn

    Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. The immediate release tablet of Zileuton has been withdrawn from the US market.

  6. Drug

    Tositumomab

    go.drugbank.com/drugs/DB00081
    ApprovedWithdrawn

    It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).

  7. Drug

    Opebacan

    go.drugbank.com/drugs/DB06161
    Investigational

  8. Drug

    Dexfenfluramine

    go.drugbank.com/drugs/DB01191
    ApprovedIllicitWithdrawn

    For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. … Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug.

    Synonyms: (S)-fenfluramine, (S)-N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine
  9. Drug

    Enrasentan

    go.drugbank.com/drugs/DB06460
    Experimental

  10. Drug

    MG98

    go.drugbank.com/drugs/DB06544
    Experimental

    MG98, a second-generation antisense oligodeoxynucleotide inhibitor of human DNMT1, was investigated in the completed clinical trial NCT00003890 for treating patients with advanced solid tumors.